Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Debenhams Raised After Strong Report

Fri, 17th Apr 2015 08:58

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
---------
FTSE 100
----------
CANACCORD RAISES SMITHS GROUP PRICE TARGET TO 1410 (1390) PENCE - 'HOLD'
----------
EXANE BNP RAISES SMITHS GROUP PRICE TARGET TO 1150 (1050) PENCE - 'NEUTRAL'
----------
NOMURA RAISES SMITHS GROUP PRICE TARGET TO 1400 (1320) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES SMITHS GROUP PRICE TARGET TO 1520 (1310) PENCE - 'OVERWEIGHT'
----------
EXANE BNP RAISES WEIR GROUP PRICE TARGET TO 1925 (1500) PENCE
----------
EXANE BNP RAISES WEIR GROUP TO 'NEUTRAL' ('UNDERPERFORM')
----------
EXANE BNP CUTS GKN TO 'NEUTRAL' ('OUTPERFORM') - TARGET 380 PENCE
----------
CREDIT SUISSE RAISES WHITBREAD PRICE TARGET TO 6200 (5300) PENCE - 'OUTPERFORM'
----------
CANACCORD RAISES KINGFISHER PRICE TARGET TO 334 (300) PENCE - 'HOLD'
----------
CANACCORD RAISES DIAGEO PRICE TARGET TO 1515 (1465) PENCE - 'SELL'
----------
JPMORGAN RAISES UNILEVER PLC PRICE TARGET TO 2900 (2750) PENCE - 'UNDERWEIGHT'
----------
Liberum Raises Unilever Price Target To 2,400p From 2,310p, Reiterates Sell
----------
JPMORGAN RAISES SABMILLER PRICE TARGET TO 4000 (3650) PENCE - 'OVERWEIGHT'
----------
UBS RAISES SABMILLER PRICE TARGET TO 3600 (3500) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES SABMILLER PRICE TARGET TO 3920 (3700) PENCE - 'BUY'
----------
Berenberg Raises SABMiller Price Target To 3,920p From 3,700p, Reiterates Buy
----------
DAVY INITIATES ROYAL MAIL WITH 'UNDERPERFORM' - TARGET 380 PENCE
----------
GOLDMAN RAISES MEGGITT PRICE TARGET TO 592 (573) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BAE SYSTEMS PRICE TARGET TO 611 (577) PENCE - 'BUY'
----------
DEUTSCHE BANK RAISES ASTRAZENECA PRICE TARGET TO 4850 (4800) PENCE - 'HOLD'
----------
DEUTSCHE BANK RAISES SHIRE PRICE TARGET TO 5900 (5700) PENCE - 'BUY'
----------
FTSE 250
----------
EXANE BNP RAISES MELROSE INDUSTRIES TARGET TO 315 (300) PENCE - 'OUTPERFORM'
----------
CANACCORD CUTS PETRA DIAMONDS PRICE TARGET TO 220 (230) PENCE - 'BUY'
----------
EXANE BNP CUTS VESUVIUS PRICE TARGET TO 515 (540) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES SPIRAX-SARCO PRICE TARGET TO 3550 (3500) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS ROTORK PRICE TARGET TO 2600 (2610) PENCE - 'NEUTRAL'
----------
BARCLAYS CUTS ROTORK TO 'EQUAL WEIGHT' ('OVERWEIGHT')
----------
EXANE BNP RAISES IMI PRICE TARGET TO 1150 (1100) PENCE - 'UNDERPERFORM'
----------
EXANE BNP RAISES HALMA PRICE TARGET TO 800 (780) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES SPECTRIS TO 'NEUTRAL' ('UNDERPERFORM') - TARGET 2375 (1850) PENCE
----------
BARCLAYS RAISES SPECTRIS PRICE TARGET TO 2535 (2065) PENCE - 'OVERWEIGHT'
----------
CREDIT SUISSE RAISES JUPITER FUND PRICE TARGET TO 430 (378) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES PLAYTECH PRICE TARGET TO 1030 (960) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS CARILLION PRICE TARGET TO 305 (330) PENCE - 'NEUTRAL'
----------
PANMURE RAISES PROVIDENT FINANCIAL PRICE TARGET TO 3000 (2700) PENCE - 'HOLD'
----------
SOCGEN RAISES DEBENHAMS PRICE TARGET TO 80 (67) PENCE - 'HOLD'
----------
UBS RAISES DEBENHAMS PRICE TARGET TO 90 (85) PENCE - 'BUY'
----------
CITIGROUP RAISES DEBENHAMS TO 'BUY' ('NEUTRAL') - TARGET 95 (75) PENCE
----------
BARCLAYS RAISES MORGAN ADVANCED MATERIALS TARGET TO 350 (305) PENCE - 'EQUALWEIGHT'
----------
BARCLAYS RAISES LAIRD PRICE TARGET TO 370 (315) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES IMI PRICE TARGET TO 1380 (1340) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES HALMA PRICE TARGET TO 715 (650) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS CUTS DOMINO PRINTING TO 'EQUAL WEIGHT' ('OVERWEIGHT')
----------
BARCLAYS RAISES DOMINO PRINTING PRICE TARGET TO 915 (730) PENCE
----------
BARCLAYS RAISES RENISHAW PRICE TARGET TO 2825 (2425) PENCE - 'OVERWEIGHT'
----------
GOLDMAN RAISES QINETIQ PRICE TARGET TO 208 (204) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES QINETIQ TO 'OVERWEIGHT' ('EQUAL WEIGHT') - TARGET 220 (210) PENCE
----------
BARCLAYS INITIATES MONEYSUPERMARKET WITH 'OVERWEIGHT' - TARGET 315 PENCE
----------
TRADERS: HSBC RAISES PENNON GROUP PRICE TARGET TO 970 (960) PENCE
----------
GOLDMAN CUTS ULTRA ELECTRONICS PRICE TARGET TO 1833 (2011) PENCE - 'NEUTRAL'
----------
GOLDMAN RESUMES COBHAM WITH 'NEUTRAL' - TARGET 329 PENCE
----------
GOLDMAN CUTS PETROFAC TO 'BUY' ('CONVICTION BUY LIST') - TARGET 1130 PENCE
----------
GOLDMAN RAISES HUNTING TO 'CONVICTION BUY' ('BUY') - TARGET 709 (622) PENCE
----------
MAIN MARKET AND AIM
----------
CANACCORD RAISES ONESAVINGS BANK TO 'BUY' ('HOLD') - TARGET 316 (290) PENCE
----------
JPMORGAN CUTS MOTHERCARE PRICE TARGET TO 235 (239) PENCE - 'OVERWEIGHT'
----------
JPMORGAN INITIATES URBAN & CIVIC WITH 'NEUTRAL' - TARGET 300 PENCE
----------
Cantor Fitzgerald Raises Chariot Oil & Gas Price Target To 20p From 12p, Reiterates Buy
----------
BARCLAYS RAISES OXFORD INSTRUMENTS PRICE TARGET TO 1000 (860) PENCE
----------
BARCLAYS RAISES OXFORD INSTRUMENTS TO 'OVERWEIGHT' ('EQUAL WEIGHT')
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.